Trial will evaluate diagnostic tests for detection of high-risk HPV types.
Third Wave Technologies selected SeqWright to participate in the clinical trial for two human papillomavirus (HPV) screening products.
SeqWright will perform all the sequencing and associated analyses in support of Third Wave’s HPV trial for evaluation of two new in vitro diagnostic molecular assays: a screening test for the detection of 14 high-risk types of HPV and a genotyping test to specifically detect and identify HPV types 16 and 18. These two HPV types have been identified as the cause of approximately 70% of cervical cancer cases.
SeqWright’s participation in this clinical trial will enable development and implementation of custom sequence analysis procedures, according to the companies.